Why the study?
Do novel oral anticoagulants overcome the limitations of vitamin K antagonists for stroke prevention in patients with atrial fibrillation?
Do novel oral anticoagulants overcome the limitations of vitamin K antagonists for stroke prevention in patients with atrial fibrillation?
Answers are grounded in this paper and cite their sources.
Novel oral anticoagulants represent a promising alternative to vitamin K antagonists for stroke prevention in atrial fibrillation, potentially improving guideline adherence and patient safety.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ricci et al. (2013) conducted a review in Atrial fibrillation. Novel oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban) vs. Vitamin K antagonists was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: